Journal articleEur J Pharmacol2023
CASP1 is a target for combination therapy in pancreatic cancer.
- Journal
- Eur J Pharmacol
- Published
- 8 November 2023
- Citations
- 14
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Gemcitabine (GEM) is commonly used as the first-line chemotherapeutic agent for treating pancreatic cancer (PC) patients. However, drug resistance is a major hurdle in GEM-based chemotherapy for PC. … Excerpt only: this text is the publisher’s. Read it in full at the source.